ClinicalTrials.gg
CompletedNCT00309244Updated Oct 16, 2014Results posted

Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up

A Phase 3 interventional study of Technosphere® Insulin Inhalation Powder and 70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin) in Diabetes Type 2, sponsored by Mannkind Corporation. Completed at 151 sites in 10 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-10-16.

Sponsored by Mannkind Corporation · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
677
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 — none open to participants now, 1 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus, Type 2.

Enrollment
3rd of 49
677 · median 129
Started
2006
with 9 others
Phase 3
25 of 49
none open now
Registered
2nd of 49
by date
Lead sponsor
13 of 49
Mannkind Corporation

Among the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2, this one is the 3rd largest by enrollment, is one of 10 that started in 2006, is one of 25 in phase 3, and was the 2nd registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About Insulin, Regular, Human

Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 as a file.
02

Study summary

The purpose of this 13 month study (12 month treatment period and 1 month follow-up period) is to determine whether inhaled insulin is safe and effective in the treatment of type 2 diabetes.

03

Conditions studied

  • Diabetes Type 2
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women ≥ 18 and ≤ 80 years old
  • Clinical diagnosis of type 2 diabetes mellitus
  • > 7.0% and ≤ 11.0%
  • ≤ 40 kg/m2
  • Negative smoking status and urine cotinine test
  • Written
  • Receiving sc insulin 2-3 times daily administered as any of the following 3 regimens: self-mix regimen, pre-mix regimen, or long-acting analogue and regular or rapid-acting insulin analogue not to exceed 3 daily injections. Subjects may also have received oral antidiabetic agents including metformin or thiazolidinediones.
  • No dose adjustments for insulin and oral antidiabetic agents within the preceding 6 weeks.
  • ≥ 70% of NHANES III predicted; TLC) ≥ 80% of predicted (Intermountain Thoracic Society); DLCO uncorrected ≥ 70% of predicted

Exclusion criteria

Exclusion Criteria:

  • Total daily dose of insulin ≥1.4 IU/kg body weight
  • Treatment with any sulfonylureas and/or meglitinides and/or alpha-glucosidase inhibitors within the preceding 8 weeks
  • Treatment with pramlintide acetate (Symlin®), and/or any incretins (e.g., exenatide [Byetta®]) within the preceding 8 weeks
  • Unstable diabetes mellitus control, defined as 2 or more episodes of severe hypoglycemia (requiring third party intervention) and/or any hospitalization or emergency room visit due to poor diabetic control or hyperglycemia requiring hospitalization within the preceding 6 months
  • Exposure to an inhaled insulin at any time, treatment with an drug within the preceding 3 months, and/or current participation in another clinical trial
  • Allergy to insulin or to any drugs to be used as part of the clinical trial, or history of to the investigational drug or to drugs of similar chemical structures
  • History of active viral and/or cirrhotic hepatic disease and/or abnormal liver enzymes as evidenced by serum (AST)and/or alanine aminotransferase (ALT) ≥ 3 x (ULN)(Includes active hepatitis A, positive and/or serology)
  • Serum creatinine > 1.8 mg/dL in women and > 2.0 mg/dL in men History of (COPD), asthma (any history of bronchospasm or asthma after the age of 14), and/or any other pulmonary disease confirmed by documented history, pulmonary function testing, or radiologic findings
  • Congestive heart disease graded as class III or class IV according to criteria and subjects currently being treated pharmacologically for ventricular dysrhythmias using amiodarone
  • History of myocardial infarction, cardiac surgery, coronary angioplasty, and/or stroke within the preceding 3 months
  • Symptomatic coronary artery disease, including crescendo angina, unstable angina, and/or unstable or symptomatic cardiac arrhythmias
  • Poorly controlled arterial hypertension despite pharmacologic treatment, defined as systolic blood pressure (BP) > 180 mm Hg and/or diastolic BP > 110 mm Hg at screening
  • History of within the preceding 5 years (other than excised basal cell carcinoma of the skin), any history of lung neoplasm, and/or subjects with current or previous chemotherapy or radiation therapy that may result in pulmonary toxicity
  • History of acquired immunodeficiency syndrome (AIDS), AIDS-related complex (ARC), or positive (HIV) serology
  • Prior diagnosis of systemic or collagen vascular disease requiring previous or current treatment with systemic , cytotoxic drugs, or penicillamine
  • Visit 1/Screening (Week -3), but prior to Visit 1 PFTs and before Visit 3/Baseline (Week 0), subject will be scheduled for PFTs after 30 days from resolution of respiratory infection. An additional and urine β-HCG (for women of age only) will be required
  • Women who are pregnant, lactating or planning to become pregnant
  • Women of childbearing potential (defined as pre-menopausal and not surgically sterilized or for less than 2 years) not practicing adequate . Adequate birth control is defined as using oral, percutaneous and/or transdermal contraceptives; condoms and diaphragms with a spermicide, or intrauterine devices
  • Current drug and/or alcohol abuse
  • Subjects who in the opinion of the Investigator will be unable to comply with the requirements of the protocol
  • Severe complications of diabetes mellitus, in the opinion of the Investigator, including: symptomatic autonomic neuropathy, disabling peripheral neuropathy, active proliferative retinopathy; nephropathy with renal failure, renal transplant and/or dialysis; history of foot ulcers; nontraumatic amputations due to gangrene;and/or vascular claudication
  • Any other concurrent medical or major psychiatric condition which, in the opinion of the Investigator, makes the subject unsuitable for the clinical trial, or could limit the validity of the ICF and/or impair the subject's ability to participate in the trial
  • Inability to perform PFT maneuvers meeting recommended American Thoracic Society (ATS) acceptability and repeatability criteria.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
677 participants (actual)

Study arms

  • Experimental
    TI + Insulin glargine

    Technosphere® Insulin Inhalation Powder + insulin glargine

    Drug: Technosphere® Insulin Inhalation Powder

  • Active comparator
    BPR 70/30

    70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)

    Drug: 70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)

Interventions

  • Inhalation, 15U/30U

  • Drug70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)

    BPR 70/30, which is a premix of intermediate acting and rapid acting insulin given sc

06

What researchers measure

Primary outcomes

  1. Change From Baseline in HbA1c to Week 52

    Time frame: Baseline to Week 52

Secondary outcomes

  1. Change From Baseline in Weight to Week 52

    Time frame: Baseline to Week 52

  2. Change From Baseline in Fasting Plasma Glucose to Week 52

    Time frame: Baseline to Week 52

  3. Number of Subjects Achieving Week 52 HbA1c Levels Less Than or Equal to 7.0%

    Time frame: Week 52

  4. Incidence of Total Hypoglycemia

    Defined as hypoglycemic symptoms that are relieved with carbohydrate intake or blood glucose measurement \<= 63 mg/dL, regardless of symptoms.

    Time frame: 52 Weeks

  5. Incidence of Severe Hypoglycemia

    Severe hypoglycemia occurs when all 3 of the following occur simultaneously: * Subject requires the assistance of another person; * Subject exhibits at least 1 cognitive neurological symptom (memory loss, confusion, uncontrollable behavior, irrational behavior, unusual difficulty in awakening, seizure, loss of consciousness); * Measured BG is ≤ 49 mg/dL (2.7 mmol/L), or, in the absence of a BG measurement, clinical symptoms are reversed by oral carbohydrates, sc glucagon or intravenous glucose administration; OR, * Measured BG is ≤ 36 mg/dL (2.0 mmol/L) with or without symptoms.

    Time frame: 52 Weeks

  6. Total Hypoglycemia Event Rate

    Number of Hypoglycemic Events/Total Subject Exposure Time (in months)

    Time frame: 52 Weeks

  7. Severe Hypoglycemia Event Rate

    Number of Severe Hypoglycemic Events/Total Subject Exposure Time (in months)

    Time frame: 52 Weeks

07

Results

Posted Oct 16, 2014

Participant flow

First subject enrolled Feb. 23, 2006 Multi-national trial conducted in US, Canada, Mexico, Brazil, Argentina, Chile, Spain, UK, Poland, Russia

Participant flow — Overall Study
MilestoneTI + Insulin GlargineBPR 70/30
Started334343
Completed216246
Not completed11897
Withdrew: Adverse event2912
Withdrew: Lost to follow-up622
Withdrew: Physician decision58
Withdrew: Protocol violation63
Withdrew: Withdrawal by subject5032
Withdrew: Various77
Withdrew: Randomized but not dosed1112
Withdrew: Death41

Outcome measures

PrimaryChange From Baseline in HbA1c to Week 52
Time frame:
Baseline to Week 52
Reported as:
Least squares mean · percent
Change From Baseline in HbA1c to Week 52
percentTI + Insulin GlargineBPR 70/30
Change From Baseline in HbA1c to Week 52-0.59 ± 0.063-0.71 ± 0.061
Statistical analysis
  • TI + Insulin Glargine vs BPR 70/30 · ANCOVA · Mean difference (final values): 0.12 · 95% CI -0.05 to 0.29
SecondaryChange From Baseline in Weight to Week 52
Time frame:
Baseline to Week 52
Reported as:
Least squares mean · kilogram
Change From Baseline in Weight to Week 52
kilogramTI + Insulin GlargineBPR 70/30
Change From Baseline in Weight to Week 520.9 ± 0.322.5 ± 0.29
Statistical analysis
  • TI + Insulin Glargine vs BPR 70/30 · ANCOVA · p = 0.0002 · Mean difference (net): -1.6 · 95% CI -2.4 to -0.7
SecondaryChange From Baseline in Fasting Plasma Glucose to Week 52
Time frame:
Baseline to Week 52
Reported as:
Least squares mean · milligrams per deciliter
Change From Baseline in Fasting Plasma Glucose to Week 52
milligrams per deciliterTI + Insulin GlargineBPR 70/30
Change From Baseline in Fasting Plasma Glucose to Week 52-35.7 ± 4.61-17.9 ± 4.21
Statistical analysis
  • TI + Insulin Glargine vs BPR 70/30 · ANCOVA · p = 0.0029 · Mean difference (net): -17.7 · 95% CI -29.3 to -6.1
SecondaryNumber of Subjects Achieving Week 52 HbA1c Levels Less Than or Equal to 7.0%
Time frame:
Week 52
Reported as:
Number · participants
Number of Subjects Achieving Week 52 HbA1c Levels Less Than or Equal to 7.0%
participantsTI + Insulin GlargineBPR 70/30
Number of Subjects Achieving Week 52 HbA1c Levels Less Than or Equal to 7.0%4765
Statistical analysis
  • TI + Insulin Glargine vs BPR 70/30 · Regression, Logistic · p = 0.2793 · Odds ratio (or): 0.774 · 95% CI 0.486 to 1.231
SecondaryIncidence of Total Hypoglycemia

Defined as hypoglycemic symptoms that are relieved with carbohydrate intake or blood glucose measurement \<= 63 mg/dL, regardless of symptoms.

Time frame:
52 Weeks
Reported as:
Number · percentage of participants
Incidence of Total Hypoglycemia
percentage of participantsTI + Insulin GlargineBPR 70/30
Incidence of Total Hypoglycemia47.9968.58
Statistical analysis
  • TI + Insulin Glargine vs BPR 70/30 · Regression, Logistic · p = <0.001 · Odds ratio (or): 0.423 · 95% CI 0.307 to 0.581Model: Treatment + Site
SecondaryIncidence of Severe Hypoglycemia

Severe hypoglycemia occurs when all 3 of the following occur simultaneously: * Subject requires the assistance of another person; * Subject exhibits at least 1 cognitive neurological symptom (memory loss, confusion, uncontrollable behavior, irrational behavior, unusual difficulty in awakening, seizure, loss of consciousness); * Measured BG is ≤ 49 mg/dL (2.7 mmol/L), or, in the absence of a BG measurement, clinical symptoms are reversed by oral carbohydrates, sc glucagon or intravenous glucose administration; OR, * Measured BG is ≤ 36 mg/dL (2.0 mmol/L) with or without symptoms.

Time frame:
52 Weeks
Reported as:
Number · percentage of participants
Incidence of Severe Hypoglycemia
percentage of participantsTI + Insulin GlargineBPR 70/30
Incidence of Severe Hypoglycemia4.339.97
Statistical analysis
  • TI + Insulin Glargine vs BPR 70/30 · Regression, Logistic · p = 0.0066 · Odds ratio (or): 0.409 · 95% CI 0.215 to 0.780Model: Treatment + Site
SecondaryTotal Hypoglycemia Event Rate

Number of Hypoglycemic Events/Total Subject Exposure Time (in months)

Time frame:
52 Weeks
Reported as:
Number · Number of events/subject-month
Total Hypoglycemia Event Rate
Number of events/subject-monthTI + Insulin GlargineBPR 70/30
Total Hypoglycemia Event Rate0.410.61
Statistical analysis
  • TI + Insulin Glargine vs BPR 70/30 · Generalized Estimation Equation · p = 0.0027Based on Poisson distribution
SecondarySevere Hypoglycemia Event Rate

Number of Severe Hypoglycemic Events/Total Subject Exposure Time (in months)

Time frame:
52 Weeks
Reported as:
Number · Number of events/100 subject-months
Severe Hypoglycemia Event Rate
Number of events/100 subject-monthsTI + Insulin GlargineBPR 70/30
Severe Hypoglycemia Event Rate0.732.20
Statistical analysis
  • TI + Insulin Glargine vs BPR 70/30 · Generalized Estimating Equation · p = 0.0591Based on Poission distribution

Adverse events

Collected over From first dose to 30 days after last dose. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TI + Insulin Glargine—37/323 (11.5%)225/323 (69.7%)
BPR 70/30—31/331 (9.4%)251/331 (75.8%)
Most frequent serious events
Showing 10 of 91
Most frequent serious events
EventTI + Insulin GlargineBPR 70/30
HypoglycaemiaMetabolism and nutrition disorders3/3236/331
Loss of consciousnessNervous system disorders1/3233/331
Atrial fibrillationCardiac disorders2/3231/331
Coronary artery diseaseCardiac disorders2/3230/331
DizzinessNervous system disorders2/3230/331
Angina pectorisCardiac disorders0/3232/331
Coronary artery insufficiencyCardiac disorders0/3232/331
CholecystitisHepatobiliary disorders0/3232/331
CholelithiasisHepatobiliary disorders0/3232/331
AppendicitisInfections and infestations0/3232/331
Most frequent other events
Most frequent other events
EventTI + Insulin GlargineBPR 70/30
HypoglycaemiaMetabolism and nutrition disorders155/323228/331
CoughRespiratory, thoracic and mediastinal disorders106/32320/331
Upper respiratory tract infectionInfections and infestations39/32324/331
NasopharyngitisInfections and infestations30/32328/331
Urinary tract infectionInfections and infestations10/32321/331
InfluenzaInfections and infestations18/32318/331
HeadacheNervous system disorders18/32312/331

Baseline characteristics

Safety population (23 Subjects randomized but never dosed are not included).

Age, Continuous
Age, Continuous(years)TI + Insulin GlargineBPR 70/30Total
Mean55.9 ± 10.6855.9 ± 9.9155.9 ± 10.29
Sex: Female, Male
Sex: Female, Male(Participants)TI + Insulin GlargineBPR 70/30Total
Female160185345
Male163146309
Fasting Plasma Glucose (FPG)
Fasting Plasma Glucose (FPG)(milligrams per deciliter)TI + Insulin GlargineBPR 70/30Total
Mean171.8 ± 68.53176.2 ± 67.15174 ± 67.82
HbA1c
HbA1c(percentage)TI + Insulin GlargineBPR 70/30Total
Mean8.7 ± 1.148.7 ± 1.108.7 ± 1.12
Weight
Weight(kilogram)TI + Insulin GlargineBPR 70/30Total
Mean88.1 ± 17.3385.7 ± 18.0786.9 ± 17.74
08

Study locations

151 sites
  • Coastal Clinical Research Inc
    Mobile, Alabama 36608, United States
  • Quality of Life Medical & Research Center
    Tucson, Arizona 85712, United States
  • Southern Arizona VA Healthcare System
    Tucson, Arizona 85723, United States
  • Tucson Clinical Research
    Tucson, Arizona 85741, United States
  • International Clinical Research Network
    Chula Vista, California 91911, United States
  • Saad Hijazi MD Inc
    Fresno, California 93710, United States
  • Valley Research
    Fresno, California 93720, United States
  • Diabetes/Lipid Management and Research Center
    Huntington Beach, California 92648, United States
  • South Bay Clinical Research
    Inglewood, California 90301, United States
  • Southern California Endocrine Center
    Pasadena, California 91105, United States
  • Coastal Biomedical Research Inc
    Santa Monica, California 90404, United States
  • Diabetes Research Center
    Tustin, California 92780, United States
  • University of Miami Diabetes Research Institute
    Miami, Florida 33136, United States
  • International Research Associates LLC
    Miami, Florida 33156, United States
  • Laureate Clinical Research Group
    Atlanta, Georgia 30308, United States
  • Atlanta Pharmaceutical Research Center
    Dunwoody, Georgia 30338, United States
  • North Atlanta Endocrinology & Diabetes PC
    Lawrenceville, Georgia 30045, United States
  • Atlanta Center for Clinical Research
    Roswell, Georgia 30075, United States
  • John H Stoger Jr Hospital of Cook County
    Chicago, Illinois 60612, United States
  • Clintell Inc
    Skokie, Illinois 60076, United States
  • Clintell Inc (Ellyin)
    Skokie, Illinois 60077, United States
  • Medical Research of Louisiana
    Metairie, Louisiana 70002, United States
  • Joslin Diabetes Center University of Maryland Medicine
    Baltimore, Maryland 21201, United States
  • James A Dicke MDPA
    Towson, Maryland 21204, United States
  • Wayne State University
    Detroit, Michigan 48201, United States
  • Michigan Institute of Medicine
    Livonia, Michigan 48152, United States
  • KMED Research
    St Clair Shores, Michigan 48081, United States
  • Radiant Research Inc (Minneapolis)
    Edina, Minnesota 55435, United States
  • International Diabetes Center
    Minneapolis, Minnesota 55416, United States
  • Center for Urologic Clinical Trials University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • MedEx Healthcare Research Inc
    St Louis, Missouri 63117, United States
  • Amin Radparvar's Private Practice
    St Peters, Missouri 63376, United States
  • Billings Clinic Research Division
    Billings, Montana 59101, United States
  • Montana Health Research Institute
    Billings, Montana 59102, United States
  • Creighton Diabetes Center
    Omaha, Nebraska 68131, United States
  • New Mexico Clinical Research & Osteoporosis Center
    Albuquerque, New Mexico 87106, United States
  • University of New Mexico HCS
    Albuquerque, New Mexico 87131, United States
  • Winthrop University Hospital
    Mineola, New York 11501, United States
  • North Shore Diabetes and Endocrine Associates
    New Hyde Park, New York 11042, United States
  • Univeristy of Physicians Group Endocrine Division
    Staten Island, New York 10301, United States
  • Sensenbrenner Primary Care
    Charlotte, North Carolina 28277, United States
  • East Carolina University (Tanenberg)
    Greenville, North Carolina 27834, United States
  • Physician's East PA
    Greenville, North Carolina 27834, United States
  • Valley Medical Primary Care
    Centerville, Ohio 45459, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Providence Health Partners - Center of Clinical Research
    Dayton, Ohio 45439, United States
  • Cleveland Clinic Health System
    East Cleveland, Ohio 44112, United States
  • Wells Institute for Health Awareness
    Kettering, Ohio 45429, United States
  • Oregon Medical Group Clinical Resesarch
    Eugene, Oregon 97401, United States
  • Lane Medical Research Group
    Eugene, Oregon 97404, United States
  • Portland Diabetes & Endocrinology Center
    Portland, Oregon 97210, United States
  • New Hope Research of Oregon
    Portland, Oregon 97219, United States
  • Covance CRU Inc.
    Portland, Oregon 97239, United States
  • Pennsylvania Research Institute
    Bensalem, Pennsylvania 19020, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Upstate Pharmaceutical Research
    Greenville, South Carolina 29615, United States
  • Southeastern Research Associates Inc
    Taylors, South Carolina 29687, United States
  • AM Diabetes and Endocrinology Center
    Bartlett, Tennessee 38133, United States
  • Memphis Internal Medicine PLLC
    Memphis, Tennessee 38119, United States
  • The Endocrine Clinic
    Memphis, Tennessee 38119, United States
  • Israel Hartman MD
    Arlington, Texas 76014, United States
  • South Arlington Primary Care Assoc PA
    Arlington, Texas 76017, United States
  • Dallas Diabetes & Endocrine Center
    Dallas, Texas 75230, United States
  • North Texas Endocrine Center
    Dallas, Texas 75231, United States
  • Radiant Research Dallas-North
    Dallas, Texas 75231, United States
  • Baylor Endocrine Center
    Dallas, Texas 75246, United States
  • Galenos Research
    Dallas, Texas 75251, United States
  • Spuhler Medical Associates
    Friendswood, Texas 77546, United States
  • Clinical Trial Network
    Houston, Texas 77074, United States
  • Quality Assurance Research Center Inc
    San Antonio, Texas 78205, United States
  • Covenant Clinic Research
    San Antonio, Texas 78229, United States
  • Diabetes & Glandular Disease Research Assoc PA
    San Antonio, Texas 78229, United States
  • SAM Clinical Research Center
    San Antonio, Texas 78229, United States
  • Salt Lake Research
    Salt Lake City, Utah 84107, United States
  • Sentara Medical Group
    Norfolk, Virginia 23502, United States
  • Clinical Research Associates of Tidewater
    Norfolk, Virginia 23507, United States
  • Larry D Stonesifer MD Inc PS
    Federal Way, Washington 98003, United States
  • Rainier Clinical Research Center Inc
    Renton, Washington 98055, United States
  • Cedar Research
    Tacoma, Washington 98405, United States
  • Liberty Research Center
    Tacoma, Washington 98405, United States
  • Hospital Interzonal de Agudos Pedro Fiorito
    Avellaneda, Buenos Aires B1870ARG, Argentina
  • CITDEEM - Centro de Investigacion y Tratamiento En Diabetes y Enfermedades Endocrino-Metabolicas
    San Miguel de Tucuman, Tucuman 4000, Argentina
  • FUNDAPRES/CIMel
    Buenos Aires, B1824KAJ, Argentina
  • Centro Endocrinologic Tiempo
    Buenos Aires, C1117ABH, Argentina
  • Hospital Italiano de Buenos Aires
    Buenos Aires, C1181ACH, Argentina
  • Cons Asoc de Endocrinologia
    Buenos Aires, C1425AGC, Argentina
  • Centro Medico Dra De Salvo
    Buenos Aires, C1426ABP, Argentina
  • Hospital de Clinicas de Porto Alegre
    Porto Alegre, Rio Grande do Sul 90035-903, Brazil
  • Hospital Sao Lucas da PUCRS
    Porto Alegre, Rio Grande do Sul 90610-000, Brazil
  • Universidade Estabual de Maringa
    Maringa Parana, 87020-900, Brazil
  • Nucleo de Medicina Integrada
    Mogi das Cruzes, 08780-090, Brazil
  • Instituto Estadual De Diabetes e Endocrinologia Luis Capriglione
    Rio de Janeiro, 20211-340, Brazil
  • Ccbr Brasil Centro de Analises e Pesquisas Clinicas Ltda
    Rio de Janeiro, 22271-100, Brazil
  • Hospital Guilherme Alvaro
    Santos, 11045-904, Brazil
  • CPClin-Centro de Pesquisas Clinicas
    Sao Paulo, 01244-030, Brazil
  • Hospital do Rim e Hipertensao
    Sao Paulo, 04025-011, Brazil
  • Instituto da Saude e Bem Estar da Mulher
    Sao Paulo, 04062-003, Brazil
  • Blumenau Servicos Medicos S/C Ltda
    Sao Paulo, 05302-001, Brazil
  • Centro de Pesquisa Clinica e Medicina Avancada
    Sao Paulo, 05437-010, Brazil
  • Keele Medical Place
    Downsview, Ontario M3M 3E5, Canada

Showing the first 100 of 151 sites across 10 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Peyrot M, Rubin RR. Patient-reported outcomes in adults with type 2 diabetes using mealtime inhaled technosphere insulin and basal insulin versus premixed insulin. Diabetes Technol Ther. 2011 Dec;13(12):1201-6. doi: 10.1089/dia.2011.0037. Epub 2011 Oct 14. PubMed 21999640 ↗
  • Rosenstock J, Lorber DL, Gnudi L, Howard CP, Bilheimer DW, Chang PC, Petrucci RE, Boss AH, Richardson PC. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial. Lancet. 2010 Jun 26;375(9733):2244-53. doi: 10.1016/S0140-6736(10)60632-0. PubMed 20609970 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2006, a primary completion of Aug 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 6 years 2 months after primary completion. A results delay was requested in Jun 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2006
First posted
Mar 31, 2006
Start
Feb 2006
Primary completionActual
Aug 2008
CompletionActual
Sep 2008
Results delay requested
Jun 9, 2009
Results first posted
Oct 16, 2014
Last update
Oct 16, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00309244
Responsible party
Sponsor
First posted
Mar 31, 2006
Start date
Feb 2006
Primary completion
Aug 2008
Completion
Sep 2008
Results posted
Oct 16, 2014
Last update
Oct 16, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin, Regular, Human

Start the discussion